Charles Explorer logo
🇨🇿

Long-term efficacy and safety adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body-surface-area dosing to weight-based fixed dosing in the open-label extension (OLE) of a phase III study

Publikace

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

Long-term efficacy and safety adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body-surface-area dosing to weight-based fixed dosing in the open-label extension (OLE) of a phase III study